Business
Resverlogix Establishes Clinical & Scientific Advisory Board to Support the Clinical Development of RVX-208 and Other Bromodomain Inhibitors in Neurodegenerative Diseases
TSX Exchange Symbol: RVX Dr. Bengt Winblad Appointed Chairman of the Clinical &...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n\n\nTSX Exchange Symbol: RVX \n\n\nDr. Bengt Winblad Appointed Chairman of the Clinical & Scientific\n Advisory Board\n\n\nAlzheimer's Association International Conference, Vancouver BC, July 16,\n 2012 /CNW/ - Resverlogix Corp. (TSX:RVX) today announced the formation\n of a clinical & scientific advisory board to support the clinical\n development of its lead drug candidate RVX-208 and follow-on\n bromodomain inhibitors in neurodegenerative diseases such as\n Alzheimer's disease, mild cognitive impairment and other dementias. The\n board, chaired by Dr. Bengt Winblad, will provide insight and guidance\n on all aspects of the development program.\n\n\n\"We believe cardiovascular and neurodegenerative health is linked by\n lipoproteins such as Apolipoprotein A-I (ApoA-I),\" said Dr. Jan\n Johansson, senior vice president of medical affairs at Resverlogix. \"A\n clinical program will further our understanding of how RVX-208, an\n epigenetic BET bromodomain inhibitor which increases production of Apo\n A-I, may affect neurodegenerative diseases such as early dementia or\n mild cognitive impairment.\"\n\n\nDonald McCaffrey, president and chief executive officer of Resverlogix,\n added, \"RVX-208 is the first BET bromodomain inhibitor that has emerged\n from Resverlogix' epigenetic drug discovery platform and moved into the\n clinic. It is currently in Phase 2b clinical development in patients\n with high-risk cardiovascular disease and we are eager to evaluate it\n and our other BET inhibitor compounds in other disease states.\"\n\n\nBengt Winblad, M.D., Ph.D., professor of geriatric medicine and chief\n physician at the Karolinska University Hospital, said, \"Recent studies\n are providing evidence of the link between poor cognition, memory and\n low levels of cardio-protective factors such as ApoA-I. I am looking\n forward to working with Resverlogix and studying RVX-208 in patients\n with neurodegenerative diseases.\"\n\n\nResverlogix plans to initiate a Phase 2 trial of RVX-208 in patients\n with mild cognitive impairment in the second half of 2013.\n\n\nAppointed members of the clinical & scientific advisory board include:\n\n\nBengt Winblad, M.D., Chairman: Dr. Winblad is professor of geriatric medicine and chief physician at\n the Karolinska University Hospital, Huddinge and the Karolinska\n Institute in S...